The Glucagon-like peptide-2 (GLP-2) enzyme linked immunosorbent assay (ELISA) kit provides materials for the quantitative measurement of GLP-2 in EDTA plasma and other biological fluids.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
96 well microtiter
HRP-based ELISA, colorimetric detection by dual wavelength absorbance at 450 nm and 630 nm as reference filter
6, 0.14-7.5 ng/mL
|Limit of Detection||
Glucagon-Like Peptide-2 (GLP-2) is a 33-amino acid gut hormone produced by the intestinal L-cells and various neurons in the central nervous system1-3. Posttranslational proteolytic cleavage of proglucagon molecule produces GLP-2 along with GLP-1. Intestinal GLP-2 is co-secreted along with GLP-1 upon nutrient ingestion. GLP-2 is released in response to stimulation by luminal nutrients, such as glucose, fatty acids and dietary fiber4. GLP-2 is cleaved by proteolytic enzymes into active form (1-33) and inactive form (3-33). The GLP-2 sequence is highly conserved among mammals and is involved in regulating gut mucosal growth and integrity. The main biological actions of GLP-2 are related to the regulation of energy absorption and maintenance of mucosal morphology, function and integrity of the intestine; however, recent experimental animal studies suggested that GLP-2 exerts beneficial effects on glucose metabolism in conditions related to increased uptake of energy, such as obesity. GLP-2 acts in an endocrine fashion to link intestinal growth and metabolism with nutrient intake4. GLP-2 acts as a beneficial factor for glucose metabolism in mice with high-fat diet-induced obesity5. GLP-2 and related analogs may be used as therapeutics for short bowel syndrome, Crohn’s disease, osteoporosis and as adjuvant therapy during cancer chemotherapy. Measuring plasma levels of GLP-2 in research, preclinical and clinical studies of Type 2 Diabetes and obesity will open new avenue for diagnostics and therapeutics.
1. Müller et al., (2017) The New Biology and Pharmacology of Glucagon. Physiol Rev 97: 721–766.
2. Drucker DJ, Habener JF, Holst JJ Discovery, characterization, and clinical development of the glucagon-like peptides (2017) J Clin Invest. 127(12):4217-4227.
3. Vrang N, Hansen M, Larsen PJ & Tang-Christensen M 2007 Characterization of brainstem preproglucagon projections to the paraventricular and dorsomedial hypothalamic nuclei. Brain Research 1149 118–126
4. Amato A, Baldassano and Flavia Mulè. GLP2: an underestimated signal for improving glycaemic control and insulin sensitivity. Journal of Endocrinology (2016) 229, R57–R66
5. Baldassano S, Amato A, Rappa F, Cappello F & Mulè F (2016b) Influence of endogenous glucagon like peptide-2 on lipid disorders in mice fed a high fat diet. Endocrine Research.
Vol. 41, Iss. 4,
6. HHS Publication, 5th ed., 2007. Biosafety in Microbiological and Biomedical Laboratories. Available http://www.cdc.gov/biosafety/publications/bmbl5/BMBL5
7. DHHS (NIOSH) Publication No. 78–127, August 1976. Current Intelligence Bulletin 13 – Explosive Azide Hazard. Available: http:// www.cdc.gov/niosh.
8. Kricka L. Interferences in immunoassays – still a threat. Clin Chem 2000; 46: 1037–1038.